Distinctive mortality patterns and the survival paradox in intracerebral haemorrhage subtypes: a 15-year longitudinal study
European Stroke Journal · 05.08.2026 · 11 (8)
DOI: 10.1093/esj/aakag097 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Stroke Journal, online erschienen am 18.08.2026. Verfasst von Jiann-Der Lee und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Chiayi Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Chiayi, Taiwan. Hauptthemen laut MEDLINE: Cerebral Hemorrhage. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Linkou Chang Gung memorial Hospital.
Abstract (Originalsprache)
Introduction
We investigated long-term outcomes, survival trajectories and cause-specific mortality in intracerebral haemorrhage (ICH) subtypes stratified by aetiology, location and recurrence status. Patients and methods This retrospective cohort study analysed 15,186 nontraumatic ICH patients enrolled in the multi-centre Stroke Registry of the Chang-Gung Healthcare System (SRICHS) in Taiwan (2007-2018). Registry data were linked to the Chang Gung Research Databank (clinical data, 2007-2018), the National Health Insurance Research Databank (longitudinal comorbidities, 2007-2022) and the Taiwan Death Registry (cause of death, 2007-2022). Patients were stratified into 4 subtypes: hypertensive (deep) ICH (first-ever = HICH-F and recurrent = HICH-R) and non-hypertensive including lobar ICH (first-ever = NHICH-F and recurrent = NHICH-R).
Results
Hypertensive ICH patients had a higher burden of metabolic risk factors compared to NHICH. A distinct “survival paradox” was observed in the NHICH-F group: despite having the highest initial stroke severity and 30-day mortality (22.9%, lobar = 19.5%), survivors demonstrated the best long-term survival probability among all subtypes. Conversely, HICH-F patients had the highest rate of subsequent ICH recurrence (50.5%). Recurrent ICH groups (HICH-R/NHICH-R) had the highest overall mortality (~66%), driven significantly by pneumonia and diabetes. While stroke was the most common primary cause of death across all groups, cancer was the second most common primary cause in first-ever ICH, whereas infectious and metabolic causes drove mortality in recurrent cases.
Conclusion
Long-term ICH prognosis is highly heterogeneous. First-ever non-hypertensive ICH carries high acute lethality but favourable long-term survival for 30-day survivors. In contrast, hypertensive and recurrent subtypes face a continuous risk of vascular events and comorbidity-related mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Chiayi Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Chiayi, Taiwan.
- Department of Neurology, Linkou Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Taoyuan, Taiwan.
- Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
ORCID-Profile: Tsong-Hai Lee
Förderung
- Linkou Chang Gung memorial Hospital
Zitieren
APA
Lee, J. D., Liu, C. H., Chang, T. Y., Huang, K. L., Chou, Y. C., & Lee, T. H. (2026). Distinctive mortality patterns and the survival paradox in intracerebral haemorrhage subtypes: a 15-year longitudinal study. European Stroke Journal, 11(8). https://doi.org/10.1093/esj/aakag097
Vancouver
Lee JD, Liu CH, Chang TY, Huang KL, Chou YC, Lee TH. Distinctive mortality patterns and the survival paradox in intracerebral haemorrhage subtypes: a 15-year longitudinal study. European Stroke Journal. 2026;11(8). doi:10.1093/esj/aakag097
BibTeX
@article{Lee2026,
author = {Lee, Jiann-Der and Liu, Chi-Hung and Chang, Ting-Yu and Huang, Kuo-Lun and Chou, Yi-Chun and Lee, Tsong-Hai},
title = {Distinctive mortality patterns and the survival paradox in intracerebral haemorrhage subtypes: a 15-year longitudinal study},
journal = {European Stroke Journal},
year = {2026},
volume = {11},
number = {8},
doi = {10.1093/esj/aakag097}
}
EUVIMED